The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
O'Sullivan JM., Hamblin A., Yap C., Fox S., Boucher R., Panchal A., Alimam S., Dreau H., Howard K., Ware P., Cross NCP., McMullin MF., Harrison CN., Mead AJ.